SG
IKT icon

StoneX Group’s Inhibikase Therapeutics IKT Stock Holding History

StoneX Group’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,219
Closed -$12.1K – 611
2022
Q3 		$12.1K Buy
+2,219
New +$11.7K ﹤0.01% 296

Other funds holding IKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

StoneX Group's IKT Position: Q4 2022 in Review

StoneX Group sold out of Inhibikase Therapeutics (IKT) in Q4 2022, closing a stake of 2,219 shares — an estimated $12.1K sold.

StoneX Group first reported a position in IKT in Q3 2022 and held it in 1 quarter. The position peaked at $12.1K in Q3 2022. 19 funds tracked by Wall St. Rank hold IKT as of Q4 2022.

  • StoneX Group reported no remaining Inhibikase Therapeutics position as of Q4 2022 after selling out during the quarter.
  • StoneX Group sold 2,219 Inhibikase Therapeutics shares in Q4 2022, an estimated $12.1K.
  • StoneX Group first reported a position in Inhibikase Therapeutics in Q3 2022 and held it in 1 quarter.
  • StoneX Group's Inhibikase Therapeutics position peaked at $12.1K in Q3 2022.
  • 19 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q4 2022.

Based on StoneX Group's 13F filing for Q4 2022, filed 10 Feb 2023.